The aim of this prospective, non-randomized interventional study was to assess electrophysiological effects, efficacy and safety of intravenous propafenone in termination of atrioventricular nodal reentrant tachycardia (AVNRT) and orthodromic atrioventricular reentrant tachycardia (AVRT). This single-center study was carried out at Department of Cardiology, Sestre milosrdnice University Hospita...

We determined the efficacy, pharmacokinetics, and plasma concentration-response relationships ofpropafenone, a promising new antiarrhythmic drug. Thirteen patients with frequent and complex ventricular premature beats were studied after receiving four increasing doses, during drug washout and during a randomized double-blind placebo-controlled trial, to evaluate the optimal dose in each patient...

Dear Editor, we have read with great interest the work by pintarić et al. 1 about the administration of propafenone in terminating atrioventricular nodal reentrant tachy-cardia and atrioventricular reentrant tachycardia, where propafenone is presented as a safe and efficient antiarrhythmic drug. That inspired us to present an interesting case which demonstrates how propafenone, if administered ...

The quality of sample extraction had a significant impact on mass spectrometry results. The presence of phospholipids in the sample extracts resulted in poor quantitation and also it decreases the method robustness. Here we adopted a novel sample preparation Hybrid SPE phospholipid technology to extract plasma samples for improved phospholipid removal. This new method allowed simultaneous quant...

OBJECTIVES We evaluated the safety and efficacy of ibutilide when added to propafenone in treating both paroxysmal and chronic atrial fibrillation (AF) and atrial flutter (AFL). BACKGROUND The effects of ibutilide in patients with paroxysmal or chronic AF/AFL who were pre-treated with propafenone have not been previously evaluated. METHODS Oral propafenone was initially given in 202 patient...

was effective for controlling 64% of patients, with partial control achieved in an additional 13%. The incidence of side effects necessitating drug withdrawal was 15%. In the study of Hammill et al, most patients (60%) had no significant cardiovascular disease, while 74% of Kerr’s group had primary AF without associated heart disease. We had a lower success rate than these 2 previous groups, bu...

This paper describes the development and validation of a liquid chromatography-mass spectrometric assay for propafenone and its application to a pharmacokinetic study of propafenone administered as a new propafenone hydrochloride sustained-release capsule (SR-test), as an instant-release tablet (IR-reference) and as the market leader sustained-release capsule (Rythmol, SR-reference) in male bea...

BACKGROUND Vernakalant is a new, safe and effective drug used intravenously, which has proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm compared to placebo, amiodarone, propafenone, and flecainide in clinical studies. Until now no study has been conducted comparing the perception of state of health in patients who received vernakalant versus propafenon...

The effects of the antiarrhythmic drug propafenone at Kv2.1 channels were studied with wild-type and mutated channels expressed in Xenopus laevis oocytes. Propafenone decreased the Kv2.1 currents in a time- and voltage-dependent manner (decrease of the time constants of current rise, increase of block with the duration of voltage steps starting from a block of less than 19%, increase of block w...

We determined the efficacy, pharmacokinetics, and plasma concentration-response relationships ofpropafenone, a promising new antiarrhythmic drug. Thirteen patients with frequent and complex ventricular premature beats were studied after receiving four increasing doses, during drug washout and during a randomized double-blind placebo-controlled trial, to evaluate the optimal dose in each patient...